常山藥業(300255.SZ)股價異動 尚未開展艾本那肽針對肥胖或減重的臨牀試驗
格隆匯9月24日丨常山藥業(300255.SZ)發佈公吿,公司股票交易連續10個交易日內日(2023年9月11日至9月22日)收盤價格升幅偏離值累計超過100%,根據深交所的相關規定,屬於股票交易嚴重異常波動的情況。經自查,公司不存在違反信息公平披露的情形。公司目前開展的艾本那肽臨牀試驗,適應症為治療2型糖尿病,不涉及肥胖適應症。公司尚未開展艾本那肽針對肥胖或減重的臨牀試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.